Organ Transplants: Pig Kidney Success

The shortage of human organs for transplant is a global crisis, with over 100,000 people currently on the waitlist in the United States alone. For decades, scientists have looked to xenotransplantation, the process of transplanting organs from one species to another, as a potential solution. Recently, researchers achieved a historic milestone when gene-edited pig kidneys functioned for a record duration inside brain-dead human hosts. This breakthrough offers tangible hope that an unlimited supply of organs may soon be available for patients in desperate need.

The Record-Breaking NYU Langone Study

In a landmark experiment conducted at NYU Langone Health, surgeons successfully transplanted a pig kidney into a brain-dead man and maintained its function for 61 days. This is the longest documented case of a gene-edited pig kidney functioning in a human body. The procedure was led by Dr. Robert Montgomery, the director of the NYU Langone Transplant Institute.

The study ended in September 2023, meeting its pre-determined end date. Throughout the two months, the kidney functioned much like a human organ. It produced urine and effectively filtered toxins, such as creatinine, from the blood. The medical team monitored the recipient daily and performed weekly biopsies. These tests confirmed that the cellular structure of the kidney remained healthy and showed no signs of the immediate rejection that has plagued xenotransplantation attempts in the past.

This 61-day duration is critical. Previous experiments often lasted only hours or a few days. By surpassing the two-month mark, researchers proved that the immediate immune response could be managed over a longer term. This bridges the gap between short-term experiments and the long-term reliability needed for living patients.

Understanding the Gene-Editing Process

The human immune system is designed to attack foreign tissue immediately. Pig organs are particularly difficult to transplant because they contain a sugar molecule known as alpha-gal. This sugar triggers a hyperacute rejection in humans, often destroying the transplanted organ within minutes.

To overcome this, scientists used a specific type of donor pig known as a “GalSafe” pig. These animals are engineered by Revivicor, a subsidiary of United Therapeutics Corporation. The pigs undergo a gene-editing process to “knock out” or silence the gene responsible for producing alpha-gal.

In the NYU Langone study, the approach was notably simple. The pig had only one gene modification (the removal of alpha-gal). Additionally, the surgeons transplanted the pig’s thymus gland along with the kidney. The thymus plays a vital role in the immune system. By placing it under the outer layer of the kidney, the team helped the host’s body recognize the new organ as “friend” rather than “foe.”

This single-gene edit strategy contrasts with other studies that use pigs with up to 69 genetic modifications. The success of the simpler model suggests that massive genetic re-engineering might not be necessary for the kidney to survive, potentially making the breeding and regulatory process faster and more scalable.

The Role of the "Decedent Model"

The success of these trials relies heavily on the participation of brain-dead donors, often referred to as the “decedent model.” In these cases, individuals have been declared brain dead by neurological criteria, but their heart and lung functions are maintained by machines.

Families of these individuals consent to donate the body for research rather than traditional organ donation, often because the organs were not suitable for transplant into living patients. This environment provides a perfect testing ground. It offers a fully functioning human circulatory and immune system without putting a living person at risk during the experimental phase.

The NYU study, along with similar research conducted at the University of Alabama at Birmingham (UAB), utilized this model to refine surgical techniques and immunosuppression protocols. At UAB, Dr. Jayme Locke led a study where gene-edited kidneys provided life-sustaining kidney function in a brain-dead host for seven days. This study was crucial because it proved the kidneys could clear enough waste to keep a human alive, not just that the tissue could survive.

From Research to Living Patients

While the 61-day study on a brain-dead host provided essential data, the field is moving rapidly toward living recipients. Following the success of decedent models, the FDA granted “compassionate use” authorization for transplants in living patients with no other options.

In March 2024, Richard Slayman became the first living person to receive a gene-edited pig kidney at Massachusetts General Hospital. He was discharged two weeks later, marking a major victory for the field. Although Mr. Slayman passed away almost two months later, the hospital stated there was no indication it was a result of the transplant.

Shortly after, NYU Langone performed a similar procedure on Lisa Pisano, a patient suffering from both heart and kidney failure. She received a mechanical heart pump and a gene-edited pig kidney. While the organ had to be removed after 47 days due to blood flow issues related to the heart pump, the kidney showed no signs of organ rejection.

These cases in living patients were directly enabled by the safety and efficacy data gathered during the record-breaking trials on brain-dead hosts.

Remaining Challenges and Future Availability

Despite these successes, several hurdles remain before pig kidneys become a standard treatment option.

• Zoonotic Disease: Researchers must ensure there is no risk of transmitting animal viruses to humans. Specifically, they look for Porcine Endogenous Retroviruses (PERVs). Modern gene editing creates pigs free of these active viruses to mitigate this risk.
• Long-Term Durability: While 61 days is a record, human kidney transplants need to last years or decades. Future trials will focus on the longevity of the organ.
• Regulatory Approval: The FDA requires extensive data before approving full clinical trials. The data from the 61-day study is currently being analyzed to support an Investigational New Drug (IND) application, which would allow for broader testing.

The progress made in the last two years exceeds that of the previous two decades. The successful function of these organs in brain-dead hosts has proven that the biological barriers of cross-species transplantation can be overcome.

Frequently Asked Questions

Why are pigs used for organ transplants? Pigs are the preferred candidate for xenotransplantation because their organs are roughly the same size as human organs. Additionally, pigs are easily bred, reach maturity quickly, and are already raised for food, which mitigates some ethical concerns compared to using primates.

What is the “GalSafe” pig? GalSafe pigs are a specific line of pigs genetically engineered by Revivicor. They have been modified to lack the alpha-gal sugar molecule, which is the primary cause of rapid organ rejection in humans. The FDA has also approved these pigs for human food consumption and potential therapeutic uses.

Did the kidney filter blood like a human kidney? Yes. In the NYU Langone study, the pig kidney produced urine and lowered creatinine levels, which is the standard measure of kidney function. It performed these tasks effectively for the entire 61-day duration of the study.

When will pig kidney transplants be available to the public? There is no fixed date, but the recent successes have accelerated the timeline. Researchers are currently preparing for Phase 1 clinical trials. If these trials are successful, gene-edited kidneys could become a limited option for critical patients within the next few years.